OncoMatch/Clinical Trials/NCT06799637
Study of XNW28012 in Subjects with Advanced Solid Tumors Who Failed Standard Treatments
Is NCT06799637 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies XNW28012 for advanced solid tumors.
Treatment: XNW28012 — This is an open-label, dose escalation, multicenter, phase 1, first-in-human study of XNW28012 in subjects with advanced solid tumors who have failed current standard anti-tumor therapies or are intolerant to such therapies. The study consists of two parts: a dose escalation part and a dose expansion part.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Pancreatic Cancer
Ovarian Cancer
Cervical Cancer
Biomarker criteria
Required: F3 expression testing required
Subjects who are unwilling or unable to provide tumor tissue samples that meet the requirements for tissue factor (TF) expression testing
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: established standard anti-cancer therapies
who have failed the established standard anti-cancer therapies for a given tumor type or have been intolerant to such therapies
Cannot have received: any anti-tumor therapy
Any anti-tumor therapy within 28 days prior to the first dose, including but not limited to: small molecules, immunotherapy, chemotherapy, monoclonal antibodies, or any other experimental drugs
Cannot have received: granulocyte colony stimulating factor (G-CSF, pegylated G-CSF, granulocyte / macrophage colony stimulating factor)
Have received granulocyte colony stimulating factor (G-CSF) or granulocyte / macrophage colony stimulating factor support within 1 week before screening, or pegylated G-CSF within 2 weeks before screening
Cannot have received: live vaccine
Exception: seasonal inactivated influenza vaccines allowed
Have received a live vaccine within 4 weeks prior to the first dose of study drug. Note: Seasonal vaccines for influenza are generally inactivated vaccines and are allowed; however, intranasal influenza vaccines will not be allowed if they are attenuated live vaccines.
Cannot have received: major surgery
Exception: minimally invasive procedures allowed (e.g., PICC line)
Subjects who have undergone major surgery within 28 days prior to the first dose of study drug, except if the procedure is minimally invasive (for example, introduction of peripherally inserted central catheter [PICC] line)
Lab requirements
Blood counts
adequate organ function within 7 days prior to the first study drug administration, as indicated by the laboratory values
Kidney function
adequate organ function within 7 days prior to the first study drug administration, as indicated by the laboratory values
Liver function
adequate organ function within 7 days prior to the first study drug administration, as indicated by the laboratory values
adequate organ function within 7 days prior to the first study drug administration, as indicated by the laboratory values
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify